ABNOM
☆ AI Dermatology — Free Service
Ninu awọn abajade 2022 Stiftung Warentest lati Jẹmánì, itẹlọrun alabara pẹlu ModelDerm jẹ kekere diẹ ju pẹlu awọn ijumọsọrọ telemedicine isanwo.
Ninu awọn abajade 2022 Stiftung Warentest lati Jẹmánì, itẹlọrun alabara pẹlu ModelDerm jẹ kekere diẹ ju pẹlu awọn ijumọsọrọ telemedicine isanwo.
relevance score : -100.0%
ReferencesLaser Q‑switched Nd:YAG ni a mọ̀ láti ṣe ìtòjú nevus ti Ota dáadáa àti àwọn ipo tó jọra. A ṣe ìwádìí kan láti rí bí ìmọ́lẹ̀ laser high‑fluence 1064 nm Q‑switched Nd:YAG ṣe ń ṣiṣẹ́ dáadáa lórí àwọn àyè Mongolian ní agbègbè dànì, láì fa àwọ̀ ara kí ó tàn. A ṣe ìwádìí àwọn aláìsàn 61 pẹ̀lú àwọn àyè wọ̀nyí, tí a ṣe àyẹ̀wò lapapọ̀ ọ̀gbẹ́ 70. Idájọ́ ọ̀gbẹ́ méjìlélọ́gọ́rin (70) ni a ṣe ìtòjú pẹ̀lú laser, nígbà tí àwọn míì kò ní ìtòjú fún àfíkun. A ṣe àyẹ̀wò àwọn abajade nípa lílo ìwọn àti ẹ̀rọ kan tí a ń pè ní Mexameter® láti ṣe ìwọn ìpele melanin. Àwọn aláìsàn ni a tẹ̀lé fún àkókò apapọ̀ oṣù 14 ní ẹgbẹ́ ìtòjú àti oṣù 18 ní ẹgbẹ́ àkíyèsí. Ní ìparí ìwádìí náà, a rí ìyàtò tó pọ̀jù nínú àwọn ìṣirò ìwọn àti ìpele melanin láàrin ẹgbẹ́ tí a ṣe ìtòjú àti ẹgbẹ́ tí kò ṣe ìtòjú, pẹ̀lú ẹgbẹ́ tí a ṣe ìtòjú pẹ̀lú laser tí ń fi hàn àwọn èso tó dára jù. Laser high‑fluence Q‑switched Nd:YAG, láì fa ìmọ́lẹ̀ àwọ̀ ara, fìhàn pé ó munadoko àti aláàbò fún ìtòjú àwọn àyè Mongolian dànì wọ̀nyí.
The Q-switched Nd:YAG laser is known to effectively treat nevus of Ota and similar conditions. We conducted a study to see how well a high-fluence 1064 nm Q-switched Nd:YAG laser worked on Mongolian spots in unusual areas, without causing the skin to lighten. We studied 61 patients with these spots, examining a total of 70 lesions. Half of lesions were treated with the laser, while others were left untreated for comparison. We evaluated the results using a scale and a device called a Mexameter® to measure melanin levels. Patients were followed up for an average of 14 months in the treatment group and 18 months in the observation group. At the end of the study, we found significant differences in the scale scores and melanin levels between the treated and untreated groups, with the laser-treated group showing better outcomes. The high-fluence Q-switched Nd:YAG laser, without causing skin lightening, proved effective and safe for treating these unusual Mongolian spots.
The Q-switched Nd:YAG laser is known to effectively treat nevus of Ota and similar conditions. We conducted a study to see how well a high-fluence 1064 nm Q-switched Nd:YAG laser worked on Mongolian spots in unusual areas, without causing the skin to lighten. We studied 61 patients with these spots, examining a total of 70 lesions. Half of lesions were treated with the laser, while others were left untreated for comparison. We evaluated the results using a scale and a device called a Mexameter® to measure melanin levels. Patients were followed up for an average of 14 months in the treatment group and 18 months in the observation group. At the end of the study, we found significant differences in the scale scores and melanin levels between the treated and untreated groups, with the laser-treated group showing better outcomes. The high-fluence Q-switched Nd:YAG laser, without causing skin lightening, proved effective and safe for treating these unusual Mongolian spots.
A ṣe iwadi imunadoko àti ailewu ti lilo itọju laser kan pato fún ABNOM, àti ṣàwárí àwọn ohun tí ó lè ní ipa lórí bí ó ṣe ń ṣiṣẹ́ dáadáa. A ṣàyẹ̀wò àwọn aláìsàn 110 tí ó ní ABNOM, tí wọ́n ti gba láàrin ìtòjú laser méjì sí mẹ́san. A rí i pé ìtòjú náà ṣiṣẹ́ dáadáa bí ó ti pé, ṣùgbọ́n kò dára tó fún àwọn aláìsàn àgbàlagbà. Ó tún ṣiṣẹ́ dáadáa fún àwọn aláìsàn tí ó ní awọ fẹ́rẹ̀fẹ́ (iru III) àti fún àwọn agbègbè tí ó kàn kéré (kéré jù 10 cm²). Nígbà tí melasma bá wà pẹ̀lú ABNOM, ìtòjú náà kò ní imunadoko. Awọ tàbí iye àwọn agbègbè tí ó kàn kò dàbí pé ó ní àkúnya. Fún tó 10 % àwọn aláìsàn, a rí àwọn ààyè dudu lẹ́yìn ìtòjú. Ìtòjú tó wúlò ní kutukutu lè yọrí sí àbájáde tó dára. Àwọn aláìsàn àgbàlagbà tí ó ní awọ dudu àti àwọn ààyè dudu lè ní ààyè dudu lẹ́yìn ìtòjú. Fún àwọn aláìsàn tí ó ní ABNOM àti melasma, ó dára láti lo laser agbára kékeré kí a má bà a melasma jẹ́.
To evaluate the efficacy and safety of 1064-nm Q-switched Nd:YAG laser (QSNYL) therapy for ABNOM and to identify the factors influencing the outcome. A total of 110 patients with ABNOM were retrospectively evaluated and received two-to-nine treatment sessions. The curative effect was positively correlated with the treatment time and negatively correlated with the increasing age at first treatment (p < 0.05). The curative effect was better in patients with skin type III than those with type IV ( p < 0.05) and in patients with a lesion area of less than 10 cm2 than those with a larger affected area (p < 0.05). Additionally, the treatment effect was poorer in patients with concomitant melasma (p < 0.05). The treatment effect was not significantly correlated with the lesion color or number of affected sites (p > 0.05). Eleven patients (10%) developed postinflammatory hyperpigmentation (PIH). Early and repeated QSNYL therapy achieved satisfactory results for ABNOM. The risk of PIH after laser treatment is highest among patients with older age, darker lesion color, and darker skin color. For patients with ABNOM with concurrent melasma, low-energy laser therapy is recommended to reduce the risk of melasma aggravation.
To evaluate the efficacy and safety of 1064-nm Q-switched Nd:YAG laser (QSNYL) therapy for ABNOM and to identify the factors influencing the outcome. A total of 110 patients with ABNOM were retrospectively evaluated and received two-to-nine treatment sessions. The curative effect was positively correlated with the treatment time and negatively correlated with the increasing age at first treatment (p < 0.05). The curative effect was better in patients with skin type III than those with type IV ( p < 0.05) and in patients with a lesion area of less than 10 cm2 than those with a larger affected area (p < 0.05). Additionally, the treatment effect was poorer in patients with concomitant melasma (p < 0.05). The treatment effect was not significantly correlated with the lesion color or number of affected sites (p > 0.05). Eleven patients (10%) developed postinflammatory hyperpigmentation (PIH). Early and repeated QSNYL therapy achieved satisfactory results for ABNOM. The risk of PIH after laser treatment is highest among patients with older age, darker lesion color, and darker skin color. For patients with ABNOM with concurrent melasma, low-energy laser therapy is recommended to reduce the risk of melasma aggravation.
Àwọn aṣoju funfun kò ràn lọ́́wọ́. Kò dàbí melasma, ABNOM lè dára sí i pẹ̀lú itọju laser, tí ó sì lè yọkúrò láì ní àtúnṣe àìmọ̀. Itọju laser lè ṣe ní àkókò 10 sí 20 láti tọju ABNOM.
#QS1064 laser